Double-blind, randomized, controlled clinical trial of norfloxacin for cholera.
In a double-blind, randomized clinical trial with 78 adults with acute watery diarrhea and severe dehydration, 37 subjects were positive for Vibrio cholerae. In conjunction with rehydration therapy, 13 patients received norfloxacin, 12 received trimethoprim-sulfamethoxazole (TMP-SMX), and 12 received a placebo. Norfloxacin was superior to TMP-SMX and to the placebo in reducing stool output, duration of diarrhea, fluid requirements, and vibrio excretion. TMP-SMX was no better than the placebo.
National Institute of Cholera and Enteric Diseases (ICMR), Beliaghata, Calcutta, India.
S K
SK
Bhattacharya
M K
MK
Bhattacharya
P
P
Dutta
D
D
Dutta
S P
SP
De
S N
SN
Sikdar
A
A
Maitra
A
A
Dutta
S C
SC
Pal
D000328:Adult; D002771:Cholera / Q000188:drug therapy* / Q000382:microbiology; D004311:Double-Blind Method; D005243:Feces / Q000382:microbiology; D006801:Humans; D008297:Male; D009643:Norfloxacin / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use
D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D009643:Norfloxacin